US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BioAge Labs Inc.

16.15

-0.1000-0.62%

Post-market: 16.150.00000.00%16:10 EDT

Volume:313.89K

Turnover:5.13M

Market Cap:716.73M

PE:-7.20

High:17.12

Open:16.90

Low:16.04

Close:16.25

52wk High:24.00

52wk Low:2.88

Shares:44.38M

Float Shares:28.58M

Volume Ratio:0.37

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2432

EPS(LYR):-2.2432

ROE:-27.09%

ROA:-17.76%

PB:2.63

PE(LYR):-7.20

Loading ...

Overview Company News Filings

BioAge Labs Gains on Positive BGE-102 Clinical-Trial Data

BioAge Labs announces additional interim data from Phase 1 trial of BGE-102

Bioage Announces Additional Positive Interim Phase 1 Data For BGE-102, A Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential For Best-In-Class Hscrp Reduction In Participants With Ele

Bioage Announces Additional Positive Interim Phase 1 Data for Bge-102, a Novel Brain-Penetrant Nlrp3 Inhibitor, Demonstrating Potential for Best-in-Class Hscrp Reduction in Participants With Elevated Cardiovascular Risk

THOMSON REUTERS

Bioage Labs Inc - Phase 1 Data Anticipated 1H 2026; Phase 2a Study to Initiate 1H 2026

THOMSON REUTERS

Bioage Labs Inc: Bge-102 Was Well Tolerated With a Favorable Safety Profile

THOMSON REUTERS

BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial

BioAge Labs Granted Patent Covering Novel NLRP3 Inhibitor Composition and Binding Site

BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares

BioAge Labs Raised to Equal-Weight From Underweight by Morgan Stanley

BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares

BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102

Bioage Labs Inc - Bge-102 Well-Tolerated in Sad and Initial Mad Cohorts, With a Pharmacokinetic Profile Supporting Once-Daily Oral Dosing

THOMSON REUTERS

Bioage Labs Inc - Announces Positive Interim Phase 1 Data for Bge-102, a Novel Brain-Penetrant Nlrp3 Inhibitor

THOMSON REUTERS

BioAge Labs Reports Positive Interim Phase 1 Results for BGE-102 NLRP3 Inhibitor

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

BioAge Labs Advances Clinical Programs Amid Financial Progress

Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M

BioAge Labs Doses First Participant in BGE-102 Phase 1 Trial and Reports $2.1 Million Q3 Collaboration Revenue

Bioage Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BIOA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BIOA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":16.15,"timestamp":1774641600000,"preClose":16.25,"halted":0,"volume":313890,"hourTrading":{"tag":"盘后","latestPrice":16.15,"preClose":16.15,"latestTime":"16:10 EDT","volume":8685,"amount":140258.0601,"timestamp":1774642204753,"change":0,"changeRate":0,"amplitude":0.001858},"delay":0,"changeRate":-0.0061538461538462414,"floatShares":28575500,"shares":44379800,"eps":-2.243207,"marketStatus":"Post-Mkt","change":-0.1,"latestTime":"03-27 19:41:57 EDT","open":16.9,"high":17.12,"low":16.04,"amount":5129295.558675,"amplitude":0.066462,"askPrice":16.93,"askSize":6,"bidPrice":14.28,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.243207,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774656000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":16.25,"preHourTrading":{"tag":"盘前","latestPrice":16.72,"preClose":16.25,"latestTime":"09:29 EDT","volume":5086,"amount":84253.53164999999,"timestamp":1774618195244,"change":0.47,"changeRate":0.028923,"amplitude":0.099969},"postHourTrading":{"tag":"盘后","latestPrice":16.15,"preClose":16.15,"latestTime":"16:10 EDT","volume":8685,"amount":140258.0601,"timestamp":1774642204753,"change":0,"changeRate":0,"amplitude":0.001858},"volumeRatio":0.371096,"impliedVol":0.1762,"impliedVolPercentile":0.0797},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","floatShares":28575500,"roa":"-17.76%","roe":"-27.09%","lyrEps":-2.243207,"volumeRatio":0.371096,"shares":44379800,"dividePrice":0,"high":17.12,"amplitude":0.066462,"preClose":16.25,"low":16.04,"week52Low":2.88,"pbRate":"2.63","psRate":"79.68","week52High":24,"institutionHeld":0,"latestPrice":16.15,"committee":0.886792,"eps":-2.243207,"divideRate":0,"volume":313890,"delay":0,"ttmEps":-2.243207,"open":16.9,"prevYearClose":13.23,"prevWeekClose":19.3,"prevMonthClose":22.27,"prevQuarterClose":13.23,"fiveDayClose":19.3,"twentyDayClose":22.27,"sixtyDayClose":13.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIOA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-24","symbol":"BIOA","fiscalQuarterEnding":"2025/12","expectedEps":-0.83,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-06","symbol":"BIOA","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.56},{"market":"US","date":"2025-08-06","symbol":"BIOA","fiscalQuarterEnding":"2025/06","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2025-05-06","symbol":"BIOA","fiscalQuarterEnding":"2025/03","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"post","actualEps":-0.36},{"date":"2025-03-20","symbol":"BIOA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":-0.58,"defaultRemindTime":1742500800000,"name":null,"time":"Post Market","dateTimestamp":1742443200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIOA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIOA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.1667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.1667,"analysts":6,"updateTime":1771992000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BIOA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BIOA","date":"2026-03-26","current":-7.199514,"percent":0.259358,"low":-14.88445,"twenty":-10.177522,"median":-2.511605,"eighty":-2.153802,"high":-1.532635,"avg":-5.072155,"sd":3.950198,"marketCap":728271746},"quantilePoints":[{"date":"2024-09-27","current":-10.065016,"twenty":-9.996853,"median":-9.894609,"eighty":-9.328936,"marketCap":625601139},{"date":"2024-10-04","current":-11.466752,"twenty":-11.453559,"median":-10.988513,"eighty":-9.962772,"marketCap":712727458},{"date":"2024-10-11","current":-11.290848,"twenty":-11.83725,"median":-11.290848,"eighty":-10.377246,"marketCap":701793959},{"date":"2024-10-18","current":-13.247909,"twenty":-12.852074,"median":-11.505231,"eighty":-10.913754,"marketCap":823437060},{"date":"2024-10-25","current":-13.708907,"twenty":-13.699687,"median":-12.032944,"eighty":-11.062173,"marketCap":852090807},{"date":"2024-10-31","current":-14.198716,"twenty":-13.910593,"median":-12.258321,"eighty":-11.163318,"marketCap":882535413},{"date":"2024-11-08","current":-10.411209,"twenty":-13.841443,"median":-12.631325,"eighty":-11.163318,"marketCap":738550334},{"date":"2024-11-15","current":-9.850761,"twenty":-13.741177,"median":-12.203351,"eighty":-10.879672,"marketCap":698793259},{"date":"2024-11-22","current":-9.318711,"twenty":-13.704297,"median":-11.736106,"eighty":-10.071646,"marketCap":661050728},{"date":"2024-11-29","current":-9.500638,"twenty":-13.685857,"median":-11.456511,"eighty":-9.850761,"marketCap":673956274},{"date":"2024-12-06","current":-9.283336,"twenty":-13.657045,"median":-11.290848,"eighty":-9.500638,"marketCap":658541317},{"date":"2024-12-13","current":-2.319571,"twenty":-13.258776,"median":-11.073716,"eighty":-9.298497,"marketCap":164545707},{"date":"2024-12-20","current":-2.612676,"twenty":-13.247909,"median":-10.411209,"eighty":-9.141838,"marketCap":185337975},{"date":"2024-12-27","current":-2.971476,"twenty":-13.224859,"median":-10.152544,"eighty":-7.606575,"marketCap":210790579},{"date":"2025-01-03","current":-2.809763,"twenty":-13.09117,"median":-10.065016,"eighty":-3.032119,"marketCap":199318983},{"date":"2025-01-10","current":-2.572247,"twenty":-12.858367,"median":-9.894609,"eighty":-2.886577,"marketCap":182470076},{"date":"2025-01-17","current":-2.54698,"twenty":-12.632478,"median":-9.680039,"eighty":-2.714757,"marketCap":180677639},{"date":"2025-01-24","current":-2.678371,"twenty":-12.552115,"median":-9.568861,"eighty":-2.625815,"marketCap":189998311},{"date":"2025-01-31","current":-2.415588,"twenty":-12.247327,"median":-9.318711,"eighty":-2.600547,"marketCap":171356967},{"date":"2025-02-07","current":-2.309464,"twenty":-12.16927,"median":-9.263122,"eighty":-2.51868,"marketCap":163828732},{"date":"2025-02-14","current":-2.284196,"twenty":-12.012055,"median":-9.141838,"eighty":-2.417609,"marketCap":162036295},{"date":"2025-02-21","current":-2.223554,"twenty":-11.928501,"median":-8.818412,"eighty":-2.37516,"marketCap":157734447},{"date":"2025-02-28","current":-2.208393,"twenty":-11.54371,"median":-3.087708,"eighty":-2.319571,"marketCap":156658985},{"date":"2025-03-07","current":-2.269035,"twenty":-11.466752,"median":-2.971476,"eighty":-2.294303,"marketCap":160960833},{"date":"2025-03-14","current":-2.122483,"twenty":-11.446271,"median":-2.893147,"eighty":-2.269035,"marketCap":150564699},{"date":"2025-03-21","current":-2.208204,"twenty":-11.43377,"median":-2.779442,"eighty":-2.233661,"marketCap":157023162},{"date":"2025-03-28","current":-1.956126,"twenty":-11.290848,"median":-2.7188,"eighty":-2.233661,"marketCap":139098143},{"date":"2025-04-04","current":-1.714131,"twenty":-11.203915,"median":-2.693532,"eighty":-2.213447,"marketCap":121890125},{"date":"2025-04-11","current":-1.729255,"twenty":-11.131435,"median":-2.645523,"eighty":-2.198286,"marketCap":122965626},{"date":"2025-04-17","current":-1.890585,"twenty":-11.039085,"median":-2.589935,"eighty":-2.192221,"marketCap":134437638},{"date":"2025-04-25","current":-2.117456,"twenty":-10.879672,"median":-2.54698,"eighty":-2.170997,"marketCap":150570155},{"date":"2025-05-02","current":-2.087206,"twenty":-10.498085,"median":-2.486337,"eighty":-2.155781,"marketCap":148419153},{"date":"2025-05-09","current":-2.073948,"twenty":-10.229442,"median":-2.420641,"eighty":-2.117456,"marketCap":147343652},{"date":"2025-05-16","current":-1.927611,"twenty":-10.158835,"median":-2.377687,"eighty":-2.112406,"marketCap":136947141},{"date":"2025-05-23","current":-2.038626,"twenty":-10.109042,"median":-2.344838,"eighty":-2.086198,"marketCap":144834149},{"date":"2025-05-30","current":-2.008349,"twenty":-10.078276,"median":-2.334731,"eighty":-2.073148,"marketCap":142683147},{"date":"2025-06-06","current":-2.24047,"twenty":-9.99928,"median":-2.314518,"eighty":-2.051746,"marketCap":159174164},{"date":"2025-06-13","current":-2.2657,"twenty":-9.918948,"median":-2.294303,"eighty":-2.064674,"marketCap":160966666},{"date":"2025-06-20","current":-2.215239,"twenty":-9.87707,"median":-2.284196,"eighty":-2.072748,"marketCap":157381662},{"date":"2025-06-27","current":-2.200101,"twenty":-9.785504,"median":-2.271562,"eighty":-2.073948,"marketCap":156306161},{"date":"2025-07-03","current":-2.159732,"twenty":-9.684587,"median":-2.26468,"eighty":-2.075591,"marketCap":153438158},{"date":"2025-07-11","current":-2.361576,"twenty":-9.665383,"median":-2.263661,"eighty":-2.08254,"marketCap":167778173},{"date":"2025-07-18","current":-2.422129,"twenty":-9.609795,"median":-2.271562,"eighty":-2.08404,"marketCap":172080177},{"date":"2025-07-25","current":-2.371668,"twenty":-9.500638,"median":-2.280838,"eighty":-2.084673,"marketCap":168495173},{"date":"2025-08-01","current":-2.220285,"twenty":-9.464253,"median":-2.280838,"eighty":-2.088197,"marketCap":157740162},{"date":"2025-08-08","current":-1.959737,"twenty":-9.314668,"median":-2.269035,"eighty":-2.084673,"marketCap":154872159},{"date":"2025-08-15","current":-2.023247,"twenty":-9.295465,"median":-2.262157,"eighty":-2.074957,"marketCap":159891165},{"date":"2025-08-22","current":-2.041393,"twenty":-9.27525,"median":-2.258928,"eighty":-2.064982,"marketCap":161325166},{"date":"2025-08-29","current":-2.177486,"twenty":-9.225726,"median":-2.244642,"eighty":-2.064982,"marketCap":172080177},{"date":"2025-09-05","current":-2.136658,"twenty":-9.156998,"median":-2.24047,"eighty":-2.068612,"marketCap":168853674},{"date":"2025-09-12","current":-2.227387,"twenty":-9.141838,"median":-2.24047,"eighty":-2.071948,"marketCap":176023681},{"date":"2025-09-19","current":-2.368016,"twenty":-8.95182,"median":-2.24047,"eighty":-2.073948,"marketCap":187137193},{"date":"2025-09-26","current":-2.368016,"twenty":-8.818412,"median":-2.24047,"eighty":-2.073948,"marketCap":187137193},{"date":"2025-10-03","current":-2.676493,"twenty":-8.732502,"median":-2.244642,"eighty":-2.078994,"marketCap":211515218},{"date":"2025-10-10","current":-2.472354,"twenty":-3.102868,"median":-2.258928,"eighty":-2.082165,"marketCap":195382701},{"date":"2025-10-17","current":-2.318115,"twenty":-3.072547,"median":-2.260654,"eighty":-2.08404,"marketCap":183193689},{"date":"2025-10-24","current":-3.606461,"twenty":-3.072547,"median":-2.2657,"eighty":-2.08404,"marketCap":285007794},{"date":"2025-10-31","current":-3.50666,"twenty":-3.483977,"median":-2.271562,"eighty":-2.087206,"marketCap":277120786},{"date":"2025-11-07","current":-3.533398,"twenty":-3.483977,"median":-2.280838,"eighty":-2.091294,"marketCap":267799776},{"date":"2025-11-14","current":-3.65216,"twenty":-3.543352,"median":-2.287377,"eighty":-2.091294,"marketCap":276800885},{"date":"2025-11-21","current":-4.063738,"twenty":-3.690007,"median":-2.299357,"eighty":-2.092162,"marketCap":307994767},{"date":"2025-11-28","current":-4.489508,"twenty":-3.899107,"median":-2.309042,"eighty":-2.092231,"marketCap":340264301},{"date":"2025-12-05","current":-4.967317,"twenty":-4.069415,"median":-2.318115,"eighty":-2.105866,"marketCap":376477888},{"date":"2025-12-12","current":-6.031742,"twenty":-4.3315,"median":-2.319571,"eighty":-2.109405,"marketCap":457151721},{"date":"2025-12-19","current":-5.856703,"twenty":-5.07234,"median":-2.333015,"eighty":-2.111789,"marketCap":443885358},{"date":"2025-12-26","current":-6.660935,"twenty":-5.750734,"median":-2.336346,"eighty":-2.112399,"marketCap":504838920},{"date":"2026-01-02","current":-6.258819,"twenty":-5.908741,"median":-2.336346,"eighty":-2.11442,"marketCap":474362139},{"date":"2026-01-09","current":-6.585243,"twenty":-6.05445,"median":-2.344838,"eighty":-2.11744,"marketCap":499102115},{"date":"2026-01-16","current":-10.175903,"twenty":-6.388442,"median":-2.355734,"eighty":-2.117456,"marketCap":771241845},{"date":"2026-01-23","current":-10.411813,"twenty":-6.562534,"median":-2.368016,"eighty":-2.117456,"marketCap":789121720},{"date":"2026-01-30","current":-10.521991,"twenty":-6.660935,"median":-2.37516,"eighty":-2.117837,"marketCap":797472215},{"date":"2026-02-06","current":-11.006774,"twenty":-8.674889,"median":-2.403126,"eighty":-2.119987,"marketCap":834214390},{"date":"2026-02-13","current":-10.984738,"twenty":-9.153966,"median":-2.415588,"eighty":-2.124502,"marketCap":832544291},{"date":"2026-02-20","current":-11.094916,"twenty":-9.298497,"median":-2.422129,"eighty":-2.13258,"marketCap":840894786},{"date":"2026-02-27","current":-12.295855,"twenty":-9.537248,"median":-2.429257,"eighty":-2.136658,"marketCap":931915175},{"date":"2026-03-06","current":-11.22713,"twenty":-9.787979,"median":-2.458744,"eighty":-2.147751,"marketCap":850915379},{"date":"2026-03-13","current":-10.954439,"twenty":-10.064753,"median":-2.474292,"eighty":-2.150267,"marketCap":830247905},{"date":"2026-03-20","current":-11.590717,"twenty":-10.152544,"median":-2.496444,"eighty":-2.150267,"marketCap":878472010},{"date":"2026-03-26","current":-9.035069,"twenty":-10.177522,"median":-2.511605,"eighty":-2.153802,"marketCap":728271746}],"updateTime":1774654917516},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIOA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603354780","title":"BioAge Labs Gains on Positive BGE-102 Clinical-Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2603354780","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603354780?lang=en_us&edition=fundamental","pubTime":"2026-01-13 01:10","pubTimestamp":1768237800,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs climbed after the biopharmaceutical company said it received positive interim data from a continuing clinical trial evaluating its oral drug for patients with cardiovascular risk factors.The stock recently rose 15%, to $16.08, in Monday trading. Shares have more than tripled in the past year.The Emeryville, Calif., company's lead product candidate, BGE-102, is designed to counter age-related inflammation, which has been implicated in a range of diseases including cardiovascular disease, neurodegeneration and metabolic disorders. The drug inhibits NLRP3, which the company said is the driver of such inflammation.The first BGE-102 cohort completed in obese individuals demonstrated rapid and profound reduction in inflammatory markers, the company said. On day 14 of treatment, the company said 93% of participants reached levels of blood inflammation below the clinically recognized threshold for reduced cardiovascular risk.\"We are very encouraged by these results, which","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2602545923","title":"BioAge Labs announces additional interim data from Phase 1 trial of BGE-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2602545923","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602545923?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:17","pubTimestamp":1768227448,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) announced additional positive interim data from the ongoing Phase 1 clinical trial evaluating BGE-102, a potent, structurally no...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-announces-additional-interim-data-from-phase-1-trial-of-bge-102-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-announces-additional-interim-data-from-phase-1-trial-of-bge-102-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2602545604","title":"Bioage Announces Additional Positive Interim Phase 1 Data For BGE-102, A Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential For Best-In-Class Hscrp Reduction In Participants With Ele","url":"https://stock-news.laohu8.com/highlight/detail?id=2602545604","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602545604?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:15","pubTimestamp":1768227320,"startTime":"0","endTime":"0","summary":"Jan 12 (Reuters) - BIOAGE Labs Inc ::*BIOAGE ANNOUNCES ADDITIONAL POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN-PENETRANT NLRP3 INHIBITOR, DEMONSTRATING POTENTIAL FOR BEST-IN-CLASS HSCRP RE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nRSD3qD4J2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2602543247","title":"Bioage Announces Additional Positive Interim Phase 1 Data for Bge-102, a Novel Brain-Penetrant Nlrp3 Inhibitor, Demonstrating Potential for Best-in-Class Hscrp Reduction in Participants With Elevated Cardiovascular Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543247?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:02","pubTimestamp":1768226535,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2602543245","title":"Bioage Labs Inc - Phase 1 Data Anticipated 1H 2026; Phase 2a Study to Initiate 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543245?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:02","pubTimestamp":1768226535,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2602240543","title":"Bioage Labs Inc: Bge-102 Was Well Tolerated With a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2602240543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602240543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:02","pubTimestamp":1768226535,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2602543210","title":"BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543210","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543210?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:01","pubTimestamp":1768226512,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc. announced additional positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant NLRP3 inhibitor developed for patients with cardiovascular risk factors. In the multiple ascending dose cohort, obese participants with elevated hsCRP receiving 120 mg once daily showed an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels. The study also reported significant reductions in IL-6 and fibrinogen. BGE-102 was well tolerated, with adverse events described as infrequent, mild to moderate, and self-limited, and no dose-limiting toxicities observed. Full Phase 1 data, including results from additional cohorts, are anticipated in the first half of 2026, and a Phase 2a study is planned to initiate in the same timeframe. Additional figures and data are available in the company's corporate presentation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL5wcRXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014013.SGD","SG9999014005.SGD","LU2210150020.SGD","BK4007","IE00B3QW5Z07.USD","BIOA","BK4112","NDAQ","IE00B64PRP62.GBP","SG9999014039.USD","BK4588","SG9999014021.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2602543765","title":"BioAge Labs Granted Patent Covering Novel NLRP3 Inhibitor Composition and Binding Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543765","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543765?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226416,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc. announced that a patent has been issued covering additional composition of matter and a novel NLRP3 binding site for BGE-102, a brain-penetrant small molecule NLRP3 inhibitor. The company highlighted that this patent further strengthens the intellectual property protection for BGE-102, which is being developed for the treatment of patients with cardiovascular risk factors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLMD216:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","BIOA","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","NDAQ","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","BK4007","IE00B64PRP62.GBP","BK4112","BK4588"],"gpt_icon":0},{"id":"2590541303","title":"BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541303","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541303?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:21","pubTimestamp":1765488107,"startTime":"0","endTime":"0","summary":"Paul D. Rubin, Chief Medical Officer of Bioage Labs Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL6kyPs6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2590635748","title":"BioAge Labs Raised to Equal-Weight From Underweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2590635748","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590635748?lang=en_us&edition=fundamental","pubTime":"2025-12-09 01:17","pubTimestamp":1765214220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 12:17 ET (17:17 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2589843146","title":"BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589843146","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589843146?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:21","pubTimestamp":1764976875,"startTime":"0","endTime":"0","summary":"Paul D. Rubin, Chief Medical Officer of Bioage Labs Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL3lZGrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2588887015","title":"BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887015","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887015?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:09","pubTimestamp":1764857391,"startTime":"0","endTime":"0","summary":"BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102Dec 4 (Reuters) - BIOAGE Labs Inc BIOA.O:BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2588887744","title":"Bioage Labs Inc - Bge-102 Well-Tolerated in Sad and Initial Mad Cohorts, With a Pharmacokinetic Profile Supporting Once-Daily Oral Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887744?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:08","pubTimestamp":1764857327,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0DA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2588791887","title":"Bioage Labs Inc - Announces Positive Interim Phase 1 Data for Bge-102, a Novel Brain-Penetrant Nlrp3 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2588791887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588791887?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:08","pubTimestamp":1764857327,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2588988710","title":"BioAge Labs Reports Positive Interim Phase 1 Results for BGE-102 NLRP3 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2588988710","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588988710?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856826,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc. has announced positive interim results from an ongoing Phase 1 clinical trial of BGE-102, a novel orally available, brain-penetrant NLRP3 inhibitor. The study's initial findings indicate that BGE-102 was well tolerated across single and multiple ascending dose cohorts, with a pharmacokinetic profile supporting once-daily oral dosing. BGE-102 demonstrated strong target engagement, achieving 90-98% suppression of IL-1β at Day 14, and high brain penetration at doses of 60 mg and above. The company is expanding the Phase 1 trial to include multiple ascending dose cohorts in participants with obesity and elevated hsCRP, with data from these cohorts anticipated in the first half of 2026. Full safety and efficacy analyses will follow after database lock and unblinding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL1zXW1N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU0314104364.USD","BIOA","BK4588","IE00B64PRP62.GBP","BK4007","NDAQ","BK4585","BK4112","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581886318","title":"BioAge Labs to Present at Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886318?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524021,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc., a clinical-stage biotechnology company focused on developing therapies for metabolic diseases targeting the biology of human aging, will present at the Jefferies Global Healthcare Conference in London from November 17-20, 2025. CEO Kristen Fortney and CFO Dov Goldstein are scheduled to participate in a fireside chat on November 17 and will join one-on-one meetings during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire  on November 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL89BVZr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","BK4112","BIOA","IE00B64PRP62.GBP","LU2095319765.USD","LU2210150020.SGD","BK4588","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581780190","title":"BioAge Labs Advances Clinical Programs Amid Financial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2581780190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581780190?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:03","pubTimestamp":1762495412,"startTime":"0","endTime":"0","summary":"BioAge Labs, Inc. ( ($BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors. Bi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioage-labs-advances-clinical-programs-amid-financial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioage-labs-advances-clinical-programs-amid-financial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU2065732104.USD","PRGS","BK4097","BIOA"],"gpt_icon":0},{"id":"2581046918","title":"Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046918","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046918?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:05","pubTimestamp":1762466746,"startTime":"0","endTime":"0","summary":"Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.58) by 3.45 percent. This is a 91.64 percent increase over losses of $(6.70) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48706450/bioage-labs-q3-eps-0-56-beats-0-58-estimate-sales-2-054m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","TSYW.SI","NQmain","BK4007",".IXIC","USAW.SI","BIOA","SQQQ","NVIW.SI","MNQmain","QID","QLD","TQQQ","USJW.SI"],"gpt_icon":0},{"id":"2581045158","title":"BioAge Labs Doses First Participant in BGE-102 Phase 1 Trial and Reports $2.1 Million Q3 Collaboration Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045158","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045158?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:48","pubTimestamp":1762465725,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc., a clinical-stage biopharmaceutical company focused on therapies targeting metabolic diseases and human aging, reported its third quarter 2025 financial results and provided business updates. The company announced the dosing of the first participant in its Phase 1 trial of BGE-102, an oral CNS-penetrant NLRP3 inhibitor, with initial single ascending dose data expected by the end of the year. BioAge also continued progress on its oral and parenteral APJ agonist programs, targeting investigational new drug  submissions in 2026. Collaboration revenue for the quarter ended September 30, 2025, was $2.1 million, compared to no revenue in the same period of 2024. This increase was attributed to revenue recognized under BioAge's multi-year research collaboration with Novartis, initiated in 2025. As of September 30, 2025, the company reported approximately $295.9 million in cash, cash equivalents, and marketable securities, which it estimates will be sufficient to fund operatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbGdmn6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","BIOA","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","BK4007","IE00B64PRP62.GBP","BK4112","BK4588"],"gpt_icon":0},{"id":"2581004559","title":"Bioage Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581004559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581004559?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:45","pubTimestamp":1762465500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA91RKJL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":92,"code":"91000000","status":"200"}]}}